Zhejiang Hemukang Pharmaceutical Technology Co. Ltd.

1) To evaluate the effectiveness of valsartan levamlodipine tablets (specification: 80mg/2.5mg) in the treatment of mild to moderate essential hypertension; 2) To evaluate the safety of valsartan levamlodipine tablets (specification: 80mg/2.5mg) in the treatment of mild to moderate essential hypertension.

The relative bioavailability of a single oral dose of the test preparation valsartan levoamlodipine tablets (specification: 80 mg/2.5 mg) and the reference preparations valsartan tablets (DIOVAN®, specification: 80 mg) and amlodipine besylate tablets (Norvasc®, specification: 5 mg) in healthy Chinese volunteers was studied. The pharmacokinetic parameters of the two preparations were analyzed and the bioequivalence of the two preparations after oral administration in the fed state was evaluated, so as to provide a reference for the application and clinical use of the drug.

The main purpose of the study is to study the pharmacokinetics of a single oral dose of the test preparation acetylcysteine tablets (specification: 0.6 g, Zhejiang Hemukang Pharmaceutical Technology Co., Ltd.) and the reference preparation acetylcysteine tablets (trade name (English): Fluimucil®, specification: 600 mg; ZAMBON Nederland B.V.) in humans in the fasting/fed state, and to evaluate the bioequivalence of the two preparations in the fasting/fed state. Secondary purpose of the study is to observe the safety of the test preparation acetylcysteine tablets and the reference preparation acetylcysteine tablets (trade name (English): Fluimucil®) in the fasting and fed state.